Peg-igf-i are included to increase the half-life and ...

Insulin-like growth factor I (IGF-I) has important anabolic and homeostatic functions in tissues like skeletal muscle, and

decrease circulating levels associated with catabolic conditions. While IGF-I treatment of musculoskeletal

been postulated, the dosage of homeostasis and disorders still prevents clinical use. We have developed a new

IGF-I option for site-specific addition of polyethylene glycol (PEG) to lysine 68 (PEG-IGF-I). In vitro, this modification decreased affinity to IGF-I and insulin receptors, probably by reducing the rate of association >> << and slowed Association of IGF-I-binding proteins, selectively limits quickly, but support sustainable anabolic activity. Preferably >> << the natural consequences of PEG-IGF-I are included to increase the half life and a set of IGF-binding proteins, thereby reducing the risk of hypoglycemia. PEG-IGF-I was equivalent to IGF-I to improve the reduction caused by muscle damage

in vivo without lasix 100mg affecting muscle metabolism, as IGF-I did. This data is an important step in understanding the differences

IGF-I and insulin receptor contribution in

in vivo activity of IGF-I. In addition, PEG-IGF-I presented an innovative concept for IGF-I in the treatment of diseases, indicating dysfunction of the muscles >>. <<.